Fresolimumab

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458274351

| type = mab

| mab_type = mab

| source = u

| target = TGF beta 1, 2 and 3

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 948564-73-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 375142VBIA

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09620

| chemical_formula =

| C=6392 | H=9926 | N=1698 | O=2026 | S=44

}}

Fresolimumab (GC1008) is a human monoclonal antibody{{cite journal | title = International Nonproprietary Names for Pharmaceutical Substances (INN) | journal = WHO Drug Information | volume = 23 | issue = 2 | date = 2009 | url =https://www.who.int/medicines/publications/druginformation/innlists/PLFinal101.pdf }} and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer{{cite web | title = Fresolimumab | url = http://www.cancer.gov/drugdictionary/?CdrID=530302 | work = NCI Drug Dictionary | publisher = National Cancer Institute }}{{cite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf | work = Statement on a Nonproprietary Name Adopted by the USAN Council | title = Fresolimumab }} (kidney cancer and melanoma).

It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).

History

Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists{{cite journal | vauthors = Grütter C, Wilkinson T, Turner R, Podichetty S, Finch D, McCourt M, Loning S, Jermutus L, Grütter MG | display-authors = 6 | title = A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 105 | issue = 51 | pages = 20251–6 | date = December 2008 | pmid = 19073914 | pmc = 2600578 | doi = 10.1073/pnas.0807200106 | bibcode = 2008PNAS..10520251G | doi-access = free }} and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.{{cite web | title = CAT may abandon skin drug after trial results disappoint | url = https://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html | archive-url = https://web.archive.org/web/20121103200556/https://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html | archive-date = 3 November 2012 | work = The Independent | date = 10 February 2004 | first = Stephen | last = Foley | url-status = dead | name-list-style = vanc }}

In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion.{{cite web | title = Sanofi-Aventis to buy Genzyme in search for new sales | url = https://www.bbc.co.uk/news/business-12477750 | work = BBC News | date = 16 February 2011 }}

{{as of|June 2011}} the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.{{cite web | title = Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes | date = July 5, 2011 | work = Genetic Engineering & Biotechnology News | url = http://www.genengnews.com/gen-news-highlights/scientists-trigger-white-fat-to-become-brown-fat-like-to-treat-obesty-and-type-2-diabetes/81245389/}}{{cite web | title = Studies found for Fresolimumab | url = http://www.clinicaltrials.gov/ct2/results?term=Fresolimumab | work = Clinicaltrials.gov }} On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis{{ClinicalTrialsGov|NCT01665391|A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)}} comparing fresolimumab versus placebo.

{{As of|2014|7}}, Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.{{cite web | title = R&D Portfolio | work = Sanofi | url = http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx | archive-url = https://web.archive.org/web/20140628093705/http://en.sanofi.com/rd/rd_portfolio/rd_portfolio.aspx | archive-date = 28 June 2014 }}

References

Category:Monoclonal antibodies